Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)
Launched by BOSTON UNIVERSITY · Nov 2, 1999
Trial Information
Current as of March 27, 2025
Completed
Keywords
ClinConnect Summary
To compare the short-term and long-term efficacy of two different treatment approaches in widespread use in clinical settings for treating patients with post-traumatic stress disorder (PTSD): fluoxetine (which acts directly on biological systems) vs a psychological treatment, Eye Movement Desensitization and Reprocessing (EMDR). To clarify: 1) the differential treatment effects of these different treatment modalities; 2) whether symptom improvement is accompanied by changes in pathophysiology; and 3) the long-term effectiveness of these treatments.
In recent years a variety of treatment ap...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -
- Patients must have:
- • Post-Traumatic Stress Disorder (PTSD).
Trial Officials
Bessel Van Der Kolk, MD
Principal Investigator
About Boston University
Boston University, a leading research institution located in Boston, Massachusetts, is dedicated to advancing health sciences through innovative clinical trials and research initiatives. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive network of experts and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes and addressing pressing health challenges. Boston University is committed to ethical research practices, patient safety, and the dissemination of findings to foster greater understanding and advancements in medical care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brookline, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials